Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 0.216 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; mannitol; maize starch; povidone; magnesium stearate; citric acid; sodium citrate dihydrate - temgesic sublingual tablets are indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 324 microgram/ml (equivalent: buprenorphine, qty 300 microgram/ml) - injection, solution - excipient ingredients: glucose monohydrate; hydrochloric acid; water for injections - temgesic injection is indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic injection should be employed when sublingual administration is not practical e.g. pre- or peri-operatively. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd - 13908 - suture, polyglycolic acid - hal suture ligates haemorrhoidal arteries to remove blood flow to haemorrhoids. suture is gradually absorbed by hydrolysis and metabolised. hydrolytic degradation provides a gradual loss of the tensile strength and finally dissolution of the thread after approximately 90 days. a sterile, synthetic, absorbable suture intended for applications in surgery demanding absorbable suture material. it is suitable for adapting soft tissue and for ligation. this is a single-use device.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd - 10172 - applicator, - reusable surgical instrument for endoscopic procedures.